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S U M M A R Y
We report the case of a patient with vertebral osteomyelitis and concurrent urinary tract infection (UTI)
in which extended-spectrum b-lactamase (ESBL)-producing Escherichia coli (EC1) isolated from urine
culture was ciproﬂoxacin-resistant and ertapenem/imipenem-susceptible. The empirically used oral
form of ciproﬂoxacin was switched to parenteral ertapenem based on the antimicrobial susceptibility.
However, vertebral osteomyelitis deteriorated, and despite the disappearance of pyuria and a negative
urine culture, ESBL-producing E. coli was isolated from a biopsy of the bony material from the ﬁfth
lumbar vertebra (EC2) and blood culture (EC3) at 10 and 12 days after starting ertapenem, respectively.
Ertapenem was switched to imipenem, and defervescence occurred 2 days later; a subsequent blood
culture was negative. Genotyping indicated that EC1, EC2, and EC3 were of the same clone, with the ESBL
being CTX-M-14. The tested antibiotics had identical minimum inhibitory concentrations against each of
these isolates. From the pharmacokinetics/pharmacodynamics points of view, it is reasonable to
attribute the ertapenem treatment failure in vertebral osteomyelitis due to ESBL-producing E. coli in this
case to the suboptimal ertapenem concentration in the inﬂammatory bone tissue of the host.
 2009 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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In addition to their frequent occurrence in hospitals and
healthcare facilities,1 infections due to extended-spectrum b-
lactamase (ESBL)-producing Enterobacteriaceae have become
increasingly common in the community setting.2 The worldwide
increase in infections due to ESBL-producing Enterobacteriaceae is
problematic. The importance of acquiring a better understanding
of the clinical effectiveness of antibiotics (i.e., carbapenems) in the
treatment of such infections cannot be overemphasized. Like
imipenem and meropenem, ertapenem is a carbapenem with
broad-spectrum antimicrobial activity against most ESBL-produ-
cing Enterobacteriaceae.3 We report the case of a patient with
vertebral osteomyelitis and concurrent urinary tract infection
(UTI) due to ESBL-producing Escherichia coli, which was clinically* Corresponding author. Tel.: +886 7 7317123x8304; fax: +886 7 7322402.
E-mail address: 88b0@adm.cgmh.org.tw (J.-W. Liu).
1201-9712/$36.00 – see front matter  2009 Published by Elsevier Ltd on behalf of In
doi:10.1016/j.ijid.2009.06.023refractory to treatmentwith ertapenemand subsequently cured by
treatment with imipenem. The implications of this case are
discussed.
2. Case report
In June 2007, a 56-year-old man presented to the emergency
service of our hospital complaining of dysuria of one-week
duration, frequent urination, and chills. He had also experienced
a one-month intractable dull pain in the lower back, radiating
downward to his right thigh. He had a past history of urolithiasis
involving his left kidney, and he had suffered two separate
episodes of UTI due to ESBL-E. coli at 9 and 14months earlier. Upon
admission he was afebrile and was given oral-form ciproﬂoxacin
500 mg twice daily for a presumedUTI. Movement-associated pain
prevented the patient from bending his back. His urinary and anal
sphincters were functioning normally. The peripheral white blood
cell count was 7.2  109 cells/l (normal 3.0–10.5  109 cells/l) with
a normal differential count, erythrocyte sedimentation rate wasternational Society for Infectious Diseases.
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147 U/l (normal 28–94 U/l). Urinalysis showed>20 leukocytes per
high-powered microscopic ﬁeld. Blood culture was negative for
bacterial growth. Urine culture grew E. coli (EC1; bacterial count
>100 000 colonies/ml), which was resistant to all classes of
cephalosporins, trimethoprim/sulfamethoxazole, and ciproﬂoxa-
cin andwas susceptible to ertapenem, imipenem, and gentamicin.4
EC1 was proven to be an ESBL-producing strain.
5 Urological
investigation revealed that the patient had a post-void residual
urine of 125 ml, multiple urethral strictures and left renal stone, as
well as hydronephrosis. Radiographs of the lumbar and sacral
spines showed narrowing of the intervertebral spaces between L4
and L5. Magnetic resonance imaging (MRI) disclosed heteroge-
neous enhancement over these vertebrae, suggesting L4–5
osteomyelitis (Figure 1A). Ciproﬂoxacin was switched to parent-
eral ertapenem 1000 mg per day for the additionally diagnosed
osteomyelitis on day 4. The lower back pain persisted 10 days after
starting ertapenem, and a follow-up MRI revealed progressive
vertebral osteomyelitis in L4–5 with additional development of
epidural abscess (Figure 1B). Percutaneous biopsy of the L5
vertebra was performed under computed-tomography guidance.
Histopathological examination of biopsy tissue revealed inﬁltrate
of numerous mononuclear cells interspersed with some neutro-
phils, indicating acute and chronic inﬂammation. No fungal
hyphae or spores were identiﬁed following periodic acid Schiff
and Gomorimethenamine silver staining; no bacilli were disclosedFigure 1. T1-weighted fat-suppressed contrast-enhanced MRI reveals mild increased sig
led to diminishing clarity of the vertebral end plates and narrowing of intervertebral dby acid-fast or Gram staining. Culture of the bony material biopsy
grew ESBL-E. coli (EC2). Fever developed 2 days later, and his blood
culture yielded ESBL-E. coli (EC3) despite the disappearance of
pyuria and a negative urine culture. Ertapenem was therefore
switched to imipenem. Defervescence occurred 2 days later, and a
repeated blood culture was negative for bacterial growth. The
patient received a 6-week parenteral imipenem treatment. His
recovery was uneventful, andwhen seen one year later, the patient
no longer experienced lower back pain, indicating that his
vertebral osteomyelitis had been successfully treated.
3. Bacterial identiﬁcation, susceptibility testing, and clonality
analysis
The E. coli isolates were identiﬁed by standard methods.6 ESBLs
were screened using a double-disc diffusion assay according to
Clinical and Laboratory Standards Institute (CLSI) methods.5 The
minimum inhibitory concentrations (MICs) of cefotaxime, cefo-
taxime–clavulanate, ciproﬂoxacin, ertapenem, imipenem, mero-
penem, and tigecycline were determined using Etest strips (AB
Biodisk, Solna, Sweden). The interpretation criteria were in
accordance with those suggested by the CLSI.7
Genetic relationships between isolates (EC1, EC2, and EC3) were
clariﬁed using pulsed-ﬁeld gel electrophoresis (PFGE) of the XbaI-
digested macro-fragments of the bacterial DNA.8 Two genetically
unrelated clinical E. coli isolates were used as controls in thenal intensity in L4 and L5 (A). Two weeks later, progressive vertebral enhancement
isc, and epidural abscess developed (arrow) (B).
Figure 2. The XbaI-digested DNA macro-fragment patterns of E. coli isolates (each
labeledwith EC1, EC2, and EC3) generated by pulsed-ﬁeld gel electrophoresis (PFGE).
The lanes labeled 1628 and 1927 are DNA macro-fragment patterns of genetically
unrelated E. coli isolates used as controls, and lane M represents the lambda DNA
concatmer standard for PFGE.
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criteria proposed by Tenover et al.9 To identify the b-lactamase
genes, PCR detection of the blaSHV, blaTEM, and blaCTX-M genes and a
multiplex PCRprocedure for plasmid-mediatedAmpCb-lactamase
genes were performed, as described elsewhere.8
EC1, EC2, and EC3 were ESBL-producing isolates, and the PFGE
patterns of XbaI-digested macro-fragments indicated that they
were of the same clone (Figure 2). Genes encoding SHV-1 (non-
ESBL) and CTX-M-14 b-lactamases (ESBL) were detected in all of
them, while those encoding TEM- or plasmid-mediated AmpC-
type b-lactamases were not found.
Susceptibility test results showed that the tested antibiotics
had identical MICs (mg/ml) against EC1, EC2 and EC3, as follows:
ciproﬂoxacin (>32), ertapenem (0.5), imipenem (0.12), merope-
nem (0.06), tigecycline (0.25), cefotaxime (>256), and cefotaxime–
clavulanate (4).
4. Discussion
This is a case of complicated pyogenic vertebral osteomyelitis
due to repetitive UTI in a patient with urolithiasis leading to failure
in eradication of the pathogen ESBL-E. coli. Given the intercom-
munication between the veins draining the pelvic organs and the
valveless external and internal venous plexuses of the spinal canal
(Batson’s plexus),10 the culprit microbe thus spread from the
urinary system and seeded the vertebrae leading to development
of osteomyelitis. Although CTX-M-producing E. coli isolates are
newly emerging pathogens for UTI,2 they are rarely reported to
cause vertebral osteomyelitis.
The clinical efﬁcacy a carbapenem, a time-dependent antibiotic
in terms of pharmacokinetics/pharmacodynamics, depends on the
free-form drug in the host’s serum between the dosing intervals
exceeding the MIC against the culprit pathogen that is susceptible
in vitro.11 Ertapenem, like imipenem and meropenem, has been
reported to be effective in vitro against ESBL-producing Enter-
obacteriaceae and to be clinically effective in the treatment of
infections due to these pathogens.11,12 However, ertapenem
treatment failure of osteomyelitis was found in this reported case.A variety of factors potentially lead to treatment failure in
osteomyelitis, including peripheral vascular disease,13 the pre-
sence of foreign bodies,14 bone necrosis,15 bacterial slime
production,16 heavy bacterial burden,15 and suboptimal local
antibiotic concentrations.13 Experience of the clinical treatment of
osteomyelitis with ertapenem is limited when compared to that
with imipenem or meropenem.17–19 In one experiment it was
found that the bone tissue/serum ertapenem concentration ratio
was around 0.1 at 24 h after injecting 1 g of ertapenem in
volunteers who underwent total hip replacement.20 In comparison
to imipenem and meropenem, ertapenem has a larger molecular
weight, higher plasma-protein binding afﬁnity, and a lower
volume distribution at steady states,21 making its concentrations
low in bone tissue. It is of note that the MIC of ertapenem against
the ESBL-producing E. coli in this case was 4-fold higher than that
of imipenem and 8-fold higher than that of meropenem. Taken
together, it is reasonable to attribute the failure of ertapenem
treatment of vertebral osteomyelitis in this case to the suboptimal
ertapenem concentration in the inﬂammatory bone tissue of the
host.
This case suggests that in patients with osteomyelitis,
ertapenem should be avoided if possible, or it should only be
used when the MIC of ertapenem against the pathogen is very low.
Further study is needed to conﬁrm our observation of the poor
clinical effect of ertapenem in the treatment of osteomyelitis.
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